U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07009548) titled 'CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients' on May 29.
Brief Summary: Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients. CytoGam - Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV), is an immunoglobulin G containing a standardized amount of antibody against CMV. CytoGam is obtained from pooled adult human plasma that has been selected for high anti-CMV titers. This study will evaluate if administration of CytoGam to organ transplant recipients with CMV infection, along with standard of care antiviral medic...